Pfizer and Astellas now have two studies supporting the use of Padcev with MSD's Keytruda as a perioperative therapy for ...

Shares in the company rose more than 35% on the strength of the data, which could put DBV on track to bring the immunotherapy ...

Here’s what most pharma professionals don’t want to hear: if you're a scientist or physician who spent your career in pharma, ...

Regulators in the UK and US are the first to approve GSK's Exdensur, a long-acting, twice-yearly IL-5 inhibitor for severe ...

Patients are often stabilised for years on somatostatin analogues; however, progression eventually necessitates ...

The ACIP has been accused of cherry-picking data on side effects – attempting to perpetuate a debunked link between the shots ...

GLP-1 receptor agonists have captured global attention for their ability to drive weight loss and improve metabolic health.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Alan Roth, CEO of Oxford Drug Design, about the use ...

Privately-held drug developer LIB Therapeutics has claimed FDA approval for a new once-monthly PCSK9 inhibitor – Lerochol – that can be used to reduce cholesterol levels.

And with that increasing complexity come rising costs and the risk of delays that can slow the delivery of critical medicines to patients awaiting treatments – and flatten drug sponsors’ return on ...

At ASN Kidney Week 2025, Glucagon-like peptide-1 (GLP-1) receptor agonists moved firmly into the nephrology spotlight, with ...

Enhertu is already approved as a second-line or later treatment for HER2-positive breast cancer, along with other indications ...